Investment Rating - Investment rating: Buy (maintained) [2][8] Core Views - The company is facing short-term pressure on performance in 2024, but is increasing R&D investment to build long-term advantages [2][6] - The company reported a revenue of 744 million yuan in 2024, a slight decrease of 0.17% year-on-year, and a net profit attributable to shareholders of 103 million yuan, down 54.68% year-on-year [6][9] - The company is focusing on the rehabilitation sector, which has significant long-term potential, while experiencing short-term profit pressure due to rising expense ratios [6][9] Financial Performance Summary - 2024 revenue: 744 million yuan (yoy -0.17%); net profit: 103 million yuan (yoy -54.68%); non-recurring net profit: 89.97 million yuan (yoy -55.90%) [6][11] - Q4 2024 revenue: 237 million yuan (yoy +16.74%); net profit: 29.53 million yuan (yoy -38.45%); non-recurring net profit: 25.54 million yuan (yoy -35.06%) [6][11] - Q1 2025 revenue: 186 million yuan (yoy +10.02%); net profit: 22.95 million yuan (yoy -41.26%); non-recurring net profit: 18.71 million yuan (yoy -48.72%) [6][11] Expense and Profitability Metrics - Sales expense ratio: 28.91% (yoy +6.10pct); management expense ratio: 8.10% (yoy +2.60pct); R&D expense ratio: 20.45% (yoy +6.12pct) [6][9] - Gross margin: 67.42%, down 1.20 pct year-on-year; net margin: 13.83%, down 16.82 pct year-on-year [6][9] R&D Investment and Future Outlook - R&D investment in 2024 was 152 million yuan, an increase of 42.41% year-on-year, accounting for 20.45% of total revenue [6][9] - The company has established multiple R&D centers and is focusing on advanced technologies such as brain-machine interfaces and rehabilitation robotics [7][9] - Revenue projections for 2025-2027 are 848 million yuan, 972 million yuan, and 1.121 billion yuan, with growth rates of 14.1%, 14.6%, and 15.3% respectively [8][11] Earnings Per Share and Valuation - Expected EPS for 2025-2027: 0.94 yuan, 1.21 yuan, and 1.57 yuan, with corresponding P/E ratios of 38x, 29x, and 23x [9][11]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][8] Core Views - The company's performance is under short-term pressure in 2024, but increased R&D investment is expected to build long-term advantages [2][6] - The company reported a revenue of 744 million yuan in 2024, a year-on-year decrease of 0.17%, and a net profit attributable to shareholders of 103 million yuan, down 54.68% year-on-year [6][9] - The company is focusing on the rehabilitation sector, which has significant long-term potential despite short-term profit pressures due to rising expense ratios [6][9] Financial Performance Summary - In 2024, the company achieved a revenue of 744 million yuan, with a year-on-year change of -0.17% [6][11] - The net profit attributable to shareholders was 103 million yuan, reflecting a year-on-year decline of 54.68% [6][11] - The company’s gross margin was 67.42%, down 1.20 percentage points year-on-year, and the net margin was 13.83%, down 16.82 percentage points year-on-year [6][11] - R&D expenses increased by 42.41% year-on-year to 152 million yuan, representing 20.45% of total revenue [6][11] Revenue Breakdown - Revenue from rehabilitation therapy equipment was 504 million yuan, up 9.85% year-on-year [6][9] - Revenue from rehabilitation training equipment was 165 million yuan, down 19.89% year-on-year [6][9] - Revenue from rehabilitation assessment equipment was 27.62 million yuan, down 21.92% year-on-year [6][9] Future Projections - Revenue projections for 2025, 2026, and 2027 are 848 million yuan, 972 million yuan, and 1.121 billion yuan, respectively, with growth rates of 14.1%, 14.6%, and 15.3% [8][11] - Net profit projections for the same years are 151 million yuan, 194 million yuan, and 251 million yuan, with growth rates of 46.5%, 28.8%, and 29.3% [8][11] - The expected EPS for 2025, 2026, and 2027 are 0.94 yuan, 1.21 yuan, and 1.57 yuan, respectively [8][11]

Group 1 - The core products of Zhaoli Pharmaceutical show stable growth, with a high dividend payout ratio maintained, achieving a revenue of 2.578 billion yuan in 2024, a year-on-year increase of 32.71% [8][9] - The company has significantly reduced costs and improved efficiency, with a notable decrease in expense ratios, including a sales expense ratio of 32.53%, down 7.5 percentage points year-on-year [9] - The company plans to implement an employee stock ownership plan by the end of 2024, with profit growth targets set at no less than 30% for 2025 [10] Group 2 - Weining Health's revenue for Q1 2025 was 345 million yuan, a year-on-year decrease of 30.24%, with a net profit of 5.29 million yuan, down 68.18% [11][12] - The company is focusing on cost reduction and efficiency improvement, with a significant increase in cash flow from operating activities, up 120.53% year-on-year [12] - The WiNEX product is entering a phase of mass delivery, supporting internet operations and international adaptation, with a strong digital architecture capable of handling millions of transactions [14][15] Group 3 - Lais Information's revenue for 2024 was 1.61 billion yuan, a year-on-year decrease of 3.94%, while Q1 2025 revenue dropped by 55.53% to 109 million yuan [17][18] - The company is optimizing its business structure, with significant growth in air traffic control and urban traffic management sectors, achieving revenue increases of 13.68% and 33.47% respectively [18][19] - The company is enhancing its research and development efforts, with a focus on refining its product offerings and improving operational efficiency [20] Group 4 - FenJung Media reported a revenue of 12.262 billion yuan in 2024, a year-on-year increase of 3.01%, with a net profit of 5.155 billion yuan, up 6.80% [23][25] - The company maintains a high dividend payout ratio, with cash dividends amounting to 4.766 billion yuan, representing 92.45% of net profit [24][25] - The planned acquisition of New潮传媒 is expected to enhance the company's competitive position in the outdoor advertising market [28] Group 5 - Jingwang Electronics achieved a revenue of 12.659 billion yuan in 2024, a year-on-year increase of 17.68%, with a net profit of 1.169 billion yuan, up 24.86% [30][31] - The company is expanding its production capacity, with a focus on high-end markets and AI applications, particularly in the automotive sector [32][33] - The company is increasing its R&D investments to support technological advancements and market expansion [33]

本报记者 丁蓉 外骨骼机器人未来市场空间广阔。萨摩耶云科技（深圳）集团有限公司人工智能机器人产业研究员郑扬 洋在接受《证券日报》记者采访时表示："在医疗康复领域，外骨骼机器人在帮助中风、脊髓损伤等患 者康复方面潜力巨大，预计到2030年，康养外骨骼机器人市场空间可达480亿元。在工业领域，外骨骼 机器人可辅助工人搬运重物、降低疲劳，提高工作效率和安全性，预计到2030年，市场空间可达百亿 元。此外，外骨骼机器人还能够辅助老年人行走和完成日常活动，提升其独立性和生活质量。在户外休 闲领域，随着材料轻量化、电池续航等技术突破，外骨骼机器人的渗透率将不断提升。" 商业化进程加速 近日，外骨骼机器人"出圈"。安徽黄山、山东泰山、江西武功山多个景区引入了登山辅助设备——外骨 骼机器人，这一"黑科技"受到游客青睐。 外骨骼机器人融合了人工智能、传感、人体工学、动力和电子等技术，多家A股上市公司在产业链中贡 献力量。科技部国家科技专家库专家周迪在接受《证券日报》记者采访时表示："随着技术的进步，外 骨骼机器人在医疗康复、军事、工业、出行等领域的应用场景将不断拓展，市场潜力巨大。" 应用领域广阔 "它能感知到我抬腿，并且给我 ...

Group 1 - The company Henan Xiangyu Medical Equipment Co., Ltd. has developed a transcranial magnetic-assisted therapy robot that has recently received national medical device registration, allowing it to assist in the treatment of related diseases [1] - The company is accelerating the research and development of key technologies such as embodied intelligent robots and multimodal integration, aiming to create a new highland for innovation and integrated application in the rehabilitation industry [1] - The rehabilitation science city project in Neihuang County is under construction, covering an area of 286 acres and including a high-end traditional Chinese medicine rehabilitation equipment industrial park [1] Group 2 - The Henan Guangyuan New Materials Electronic Materials Industrial Park project has officially commenced production, marking a shift towards high-grade electronic materials for artificial intelligence and high-frequency servers [2] - The project was completed in just over a year, demonstrating effective project management and execution [2] - The local government has implemented measures to stimulate economic growth, including a series of consumption promotion activities and investment expansion initiatives [3]

Investment Rating - The report assigns a "Buy" rating for Xiangyu Medical (688626) as it initiates coverage [1][7]. Core Insights - Xiangyu Medical is focusing on the development of brain-machine interfaces and rehabilitation robots, with revenue stabilizing and poised for growth [1]. - The company reported a slight decline in revenue for 2024 but showed signs of recovery in the last two quarters, with a 10% increase in Q1 2025 [4][6]. - Significant investment in R&D, with a 42% increase in 2024, indicates a commitment to maintaining technological leadership in the rehabilitation industry [6][7]. Financial Performance Summary - In 2024, the company achieved operating revenue of 744 million yuan, a decrease of 0.17% year-on-year, and a net profit of 103 million yuan, down 55% [4][6]. - For Q1 2025, revenue was 186 million yuan, reflecting a 10% increase, while net profit was 23 million yuan, a decrease of 41% [4][6]. - Revenue projections for 2025-2027 are 846 million yuan, 982 million yuan, and 1.141 billion yuan, with expected growth rates of 14%, 16%, and 16% respectively [6][8]. Profitability and Valuation Metrics - The forecasted net profits for 2025-2027 are 156 million yuan, 199 million yuan, and 255 million yuan, with growth rates of 52%, 27%, and 28% respectively [7][8]. - The projected P/E ratios for the same period are 39, 31, and 24 [7][8]. - The company maintains a strong gross margin, with 67.83% in 2024, although it is expected to slightly decline in the following years [6][9].

2024 年度持续督导工作现场检查报告 上海证券交易所： 国泰海通证券股份有限公司（以下简称"国泰海通"、"保荐人"）作为河南 翔宇医疗设备股份有限公司（以下简称"翔宇医疗"或"公司"）首次公开发行 股票并在科创板上市的保荐人，根据《中华人民共和国公司法》《中华人民共和 国证券法》《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市 规则》（以下简称"《上市规则》"）和《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有关法律法规的规定，对公司 2024 年度（以下简称"本 持续督导期间"）的规范运作情况进行了现场检查，现就现场检查的有关情况报 告如下： 一、本次现场检查的基本情况 （一）保荐人 国泰海通证券股份有限公司 国泰海通证券股份有限公司 关于河南翔宇医疗设备股份有限公司 1 （二）保荐代表人 刘君、岑平一 （三）现场检查时间 2025 年 4 月 14 日至 2025 年 4 月 17 日 （四）现场检查人员 刘君、李景玉 （五）现场检查内容 现场检查人员对本持续督导期内发行人公司治理及内部控制、信息披露、独 立性、与关联方的资金往来、募集资金使用情况、关联交易、对外担保、重 ...

Industry Insights - The CyberSense flexible microelectrode implantation robot, developed by the Brain and Brain-like Intelligence Laboratory of the Chinese Academy of Sciences, has successfully supported various flexible microelectrode implantation studies, enabling precise implantation in animal brains [1] - The brain-computer interface (BCI) industry is experiencing significant advancements in technology, leading to breakthroughs in applications such as motor recovery, language communication, and hearing restoration [1][2] - Recent policy support from the national level, including the National Healthcare Security Administration's decision to separately list prices for new BCI technologies, is paving the way for clinical application and service charge pathways [1] Company Developments - Cheng Yi Tong is a national high-tech enterprise that has expanded into the BCI-driven rehabilitation medical field through mergers and technological innovation, forming a collaborative ecosystem of "industry + medical" [3] - Xiang Yu Medical, also a national high-tech enterprise, focuses on the research, production, and sales of rehabilitation medical devices, aiming to seize opportunities in BCI medical applications amid an aging population and the "silver economy" [3]

Policy Developments - The National Medical Products Administration (NMPA) released the "Quality Management Specifications for Online Sales of Medical Devices," effective from October 1, 2025, which emphasizes qualification review, information transparency, and risk prevention for online medical device sales [1] Drug and Device Approvals - Insilico Medicine's INS018_055 tablet is expected to receive breakthrough therapy designation for treating idiopathic pulmonary fibrosis [2] - Yuyuan Pharmaceutical's injectable Ganciclovir has passed the consistency evaluation for generic drugs, which will enhance the company's market share and competitiveness [3] - Warner Pharmaceuticals' Bismuth Potassium Citrate Granules have also passed the consistency evaluation for generic drugs, benefiting future market sales [4] - Changchun High-tech's subsidiary, Jinsai Pharmaceutical, received approval for clinical trials of Fuxin Qibai monoclonal antibody injection, aimed at treating endometriosis [5] Financial Reports - Yunnan Baiyao reported a Q1 2025 net profit of 1.935 billion yuan, a 13.67% increase year-on-year, with total revenue of 10.841 billion yuan, up 0.62% [6] - WuXi AppTec's Q1 2025 net profit surged by 89.06% to 3.672 billion yuan, driven by revenue growth and operational efficiency improvements [7][8] - Kefu Medical's 2024 annual report showed a net profit increase of 22.6% to 312 million yuan, with revenue of 2.983 billion yuan, up 4.53% [9] - Hongbo Pharmaceutical's Q1 2025 net profit increased by 226.47% to 11.974 million yuan, with revenue of 16.9 million yuan, up 29.61% [10] Capital Market Activities - Jiangsu Hengrui Medicine has received approval from the China Securities Regulatory Commission for its Hong Kong IPO, planning to issue up to 815.1 million shares [11] - Merck announced its acquisition of SpringWorks for approximately $3.9 billion in equity value [12] - China Merchants Bio intends to increase its stake in Renfu Pharmaceutical by 0.5%-1% within six months, reflecting confidence in the company's future [13] Industry Developments - Xiangyu Medical expects to obtain registration certificates for seven robotic products by 2025, focusing on rehabilitation and other medical applications [14] - Soundon Medical has formed a strategic partnership with MED-EL's BHM to advance global bone conduction hearing solutions [16] - Hanyu Pharmaceutical signed a comprehensive cooperation agreement with Huawei Cloud to focus on "AI Smart Drugs" in drug development [17] Public Sentiment Alerts - Innovative Medical announced that shareholder Shanghai Guanghuan Technology reduced its stake by 3.41 million shares, representing 0.8191% of the total circulating shares [18]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][6] Core Views - The company is expected to face pressure on its performance in 2024, but the long-term logic of the rehabilitation sector remains strong [6][7] - The company achieved revenue of 744 million yuan in 2024, a year-on-year decrease of 0.17%, and a net profit attributable to shareholders of 103 million yuan, down 54.68% year-on-year [6][8] - Despite the challenges, the company is maintaining high R&D investments, which are expected to lead to new growth points in the future [6][8] Financial Summary - Revenue for 2024 is projected to be 744 million yuan, with a slight decline from 2023 [9] - The net profit for 2024 is expected to be 103 million yuan, reflecting a significant decrease compared to the previous year [9] - The company’s gross margin is forecasted to be 67.4% in 2024, slightly down from 68.6% in 2023 [9][12] - The projected earnings per share (EPS) for 2025, 2026, and 2027 are 1.04 yuan, 1.34 yuan, and 1.73 yuan respectively [9][12] Industry Outlook - The rehabilitation sector is expected to benefit from an aging population and increasing demand for rehabilitation services [7] - The company is focusing on advanced technologies such as rehabilitation robots and brain-machine interfaces, which are anticipated to create a second growth curve [8] - The integration of rehabilitation services into community health centers and township hospitals is being promoted by policy, enhancing the demand for rehabilitation solutions [7]